Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protocol-based rituximab treatment for early and severe systemic sclerosis
2006-003836-31Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in systemic sclerosis (SSc), sponsored by Ghent University Hospital. Primary endpoint: Efficacy and safety of anti-CD20 therapy. Started Aug 2006; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2006-003836-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003836-31.